2016_Head & Neck COURSE BOOK

Randomized trials mono vs polychemotherapy

Median survival (months)

Regimens

N ORR (%)

6.6 5 5.6

277

32% 21% 10%

Cisplatin/5-FU vs Carboplatin/5-FU vs Methotrexate

*Cisplatin/pemetrexed* vs Cisplatin

795

12.1% 8.%

7.3* 6.3 p= 0.082

* ECOG 0-1:

OS (8.4 vs 6.7 months; p=0.026) OS (9.9 vs 6.1 months; p=0.002)

Oropharyngeal:

Jacobs et al JCO 2002, Clavel et al Ann Oncol 1994, Forastiere et al JCO 1992, Urba et Cancer 2012